Drug interactions
Denosumab + Efgartigimod / hyaluronidase sc
Severity: Moderate
Denosumab and Efgartigimod / hyaluronidase sc: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Subcutaneous efgartigimod blocks the neonatal Fc receptor, shortening IgG half-life. Denosumab is an IgG2 monoclonal antibody and could be cleared faster, with reduced antiresorptive effect. This is predicted from mechanism rather than shown clinically.
What this interaction means in plain words
Denosumab and Efgartigimod / hyaluronidase sc can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
FcRn blockade accelerates IgG catabolism and may lower denosumab concentrations.
What to do
Monitor bone turnover markers and bone density response for reduced effectiveness. Consider alternative antiresorptive therapy if denosumab must be continued long term.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Denosumab and Efgartigimod / hyaluronidase sc, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Denosumab
- Abatacept + Denosumab Moderate
- Adalimumab + Denosumab Moderate
- Alefacept + Denosumab Moderate
- Alemtuzumab + Denosumab Moderate
- Anakinra + Denosumab Moderate
- Azacitidine + Denosumab Moderate
Frequently asked questions
Can I take Denosumab with Efgartigimod / hyaluronidase sc?
MediHelp rates the interaction as moderate. Denosumab and Efgartigimod / hyaluronidase sc can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Subcutaneous efgartigimod blocks the neonatal Fc receptor, shortening IgG half-life. Denosumab is an IgG2 monoclonal antibody and could be cleared faster, with reduced antiresorptive effect. This is predicted from mechanism rather than shown clinically.
How serious is the interaction between Denosumab and Efgartigimod / hyaluronidase sc?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor bone turnover markers and bone density response for reduced effectiveness. Consider alternative antiresorptive therapy if denosumab must be continued long term.
What other medicines interact with Denosumab?
MediHelp also lists interactions of Denosumab with, for example, Abatacept, Adalimumab, Alefacept. The full list is on the Denosumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
